In the current study, coated microneedle arrays were
fabricated
by means of digital light processing (DLP) printing. Three different
shapes were designed, printed, and coated with PLGA particles containing
two different actives. Rivastigmine (RIV) and N-acetyl-cysteine (NAC)
were coformulated via electrohydrodynamic atomization (EHDA), and
they were incorporated into the PLGA particles. The two actives are
administered as a combined therapy for Alzheimer’s disease.
The printed arrays were evaluated regarding their ability to penetrate
skin and their mechanical properties. Optical microscopy and scanning
electron microscopy (SEM) were employed to further characterize the
microneedle structure. Confocal laser microscopy studies were conducted
to construct 3D imaging of the coating and to simulate the diffusion
of the particles through artificial skin samples. Permeation studies
were performed to investigate the transport of the drugs across human
skin ex vivo. Subsequently, a series of tape strippings
were performed in an attempt to examine the deposition of the APIs
on and within the skin. Light microscopy and histological studies
revealed no drastic effects on the membrane integrity of the stratum
corneum. Finally, the cytocompatibility of the microneedles and their
precursors was evaluated by measuring cell viability (MTT assay and
live/dead staining) and membrane damages followed by LDH release.